These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30826325)

  • 1. PET/TC imaging with somatostatin analogues for assessment of neuroendocrine tumors, initial experience.
    Suárez-Piñera M; Visa Turno L; Ilzarbe L; Zugazaga A; Poves I; Mestre-Fusco A; Iglesias M
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(6):382-385. PubMed ID: 30826325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on
    Gålne A; Almquist H; Almquist M; Hindorf C; Ohlsson T; Nordenström E; Sundlöv A; Trägårdh E
    J Nucl Med; 2019 Dec; 60(12):1717-1723. PubMed ID: 31000584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of radiolabelled somatostatin analogues (
    Medina-Ornelas SS; García-Pérez FO
    Rev Esp Med Nucl Imagen Mol; 2017; 36(3):166-174. PubMed ID: 27890514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of [
    Gaertner FC; Plum T; Kreppel B; Eppard E; Meisenheimer M; Strunk H; Bundschuh RA; Sinnes JP; Rösch F; Essler M
    Nucl Med Biol; 2019; 76-77():1-9. PubMed ID: 31520872
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Delpassand ES; Ranganathan D; Wagh N; Shafie A; Gaber A; Abbasi A; Kjaer A; Tworowska I; Núñez R
    J Nucl Med; 2020 Jun; 61(6):890-896. PubMed ID: 31924723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.
    Kunikowska J; Lewington V; Krolicki L
    Clin Nucl Med; 2017 Dec; 42(12):905-911. PubMed ID: 29076910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin receptor expression in lymphomas: a source of false diagnosis of neuroendocrine tumor at
    Ruuska T; Ramírez Escalante Y; Vaittinen S; Gardberg M; Kiviniemi A; Marjamäki P; Kemppainen J; Jyrkkiö S; Minn H
    Acta Oncol; 2018 Feb; 57(2):283-289. PubMed ID: 28686510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
    Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
    Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of [
    Choi SJ; Choi SH; Lee DY; Lee JS; Kim DW; Jang JK
    Eur Radiol; 2022 Jul; 32(7):4628-4637. PubMed ID: 35092473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Radioguided surgery in neuroendocrine tumors. A review of the literature].
    García-Talavera P; Ruano R; Rioja ME; Cordero JM; Razola P; Vidal-Sicart S
    Rev Esp Med Nucl Imagen Mol; 2014; 33(6):358-65. PubMed ID: 25107596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection rate of unknown primary tumour by using somatostatin receptor PET/CT in patients with metastatic neuroendocrine tumours: a meta-analysis.
    De Dosso S; Treglia G; Pascale M; Tamburello A; Santhanam P; Kroiss AS; Pereira Mestre R; Saletti P; Giovanella L
    Endocrine; 2019 Jun; 64(3):456-468. PubMed ID: 31004334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of 68 Ga-DOTA-SSA PET/CT in the Management and Prediction of Peptide Receptor Radionuclide Therapy Response for Patients With Neuroendocrine Tumors : A Systematic Review and Meta-analysis.
    Lee ONY; Tan KV; Tripathi V; Yuan H; Chan WW; Chiu KWH
    Clin Nucl Med; 2022 Sep; 47(9):781-793. PubMed ID: 35485851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of lanreotide on uptake of
    Aalbersberg EA; de Wit-van der Veen BJ; Versleijen MWJ; Saveur LJ; Valk GD; Tesselaar MET; Stokkel MPM
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):696-703. PubMed ID: 30097670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodistribution and first clinical results of
    Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of
    Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
    J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
    Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice.
    Aalbersberg EA; Geluk-Jonker MM; Young-Mylvaganan T; de Wit-van der Veen LJ; Stokkel MPM
    J Vis Exp; 2019 Apr; (146):. PubMed ID: 31058910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative
    Norlén O; Montan H; Hellman P; Stålberg P; Sundin A
    World J Surg; 2018 Feb; 42(2):498-505. PubMed ID: 29159606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.